Click here to register for the online conferences

Here at Boucher, we would like to proudly acknowledge that NUNM, a non-profit, natural health science private university based in Portland, OR, is BINM’s active partner in continuing education development and delivery.

Gastroenterology Conference 2018

Title & DescriptionPresenter

Cost

(CE Hours)

All Presentations
Multiple presenters

$499 CAD

(12 hours)


Non-Celiac Gluten Sensitivity

In your practice, 6% of your patients, or more, have Non-Celiac Gluten Sensitivity (NCGS). Confused the difference between NCGS, non-celiac wheat sensitivity, gluten allergy, wheat food sensitivity, wheat allergy and celiac disease? Dr Shaver discusses diagnosis and reviews the research about this relatively new condition, named in 2011. There are important ethical issues to discuss with your patient prior to prescribing any of the current gluten-free diets (Keto, Paleo, Low Fodmap, Anti-Inflammatory, Wahls, etc.) if one has not thoroughly tested for NCGS and celiac disease.


Lisa Shaver, ND, LAc

$69 CAD

(1.5 hours)


Gastrointestinal Infections: Considerations and Treatment

This lecture discusses common gastrointestinal bacterial and parasitic infections and gives guidance for diagnosis and treatment. Also discussed is the importance of eradication of these infections as a key primary approach to reversing metabolic endotoxemia and establishing optimal gastrointentinal health. Prescriptive medications as well as herbal and nutraceutical treatments are discussed as well. Pharmaceuticals discussed include: Pyrantal Pamoate, Nitazoxanide, Praziquantel, Albendazole, Mebendazole, Tinidazole, Ivermectin, Iodoquinol


Anne Hill, ND

$69 CAD

(1.5 hours)


Sterol Biome

The liver synthesizes and secretes hydrophilic primary bile acids, processed in the small and large bowel by the microbiota. These enter the enterohepatic circulation and join the bile acid pool. These bile acids are hormones that regulate their own synthesis and transport as well as regulating lipid, glucose, lipoprotein and energy metabolism as well as inflammation. Dr. Sandberg-Lewis reviews the biochemistry and physiology of these processes and discuss the use of botanicals, nutrition and prescription medication to aid the activity of this essential “endocrine organ”.


Steven Sandberg-Lewis, ND

$69 CAD

(1.5 hours)


Research Updates in IBS

This presentation reviews the latest update from the Bastyr research group and affiliated international naturopathic researchers focused on whole systems naturopathic approaches to irritable bowel syndrome (IBS). Specifically, one of only a few expert consensus panels on naturopathic medicine was completed recently – The Expert Consensus for Naturopathic Approaches to IBS. A shocking 42 items of consensus were agreed upon leading to a real possibility of an external valid randomized trial of Naturopathic Approaches to IBS in the future. Our progress on the largest international observational study of naturopathic medicine to-date (the IRCNAC-IBS study) and the consortium supporting it – the first ever, international research consortium of naturopathic academic clinics – will be reviewed. Additionally, we discuss findings from the first fully naturopathically designed and executed Cochrane Review – Biofeedback to Treat IBS.


Joshua Goldenberg, ND

$69 CAD

(1.5 hours)


“Gut Healing” Protocols

This presentation takes a look at the natural agents that are most studied to heal intestinal permeability. We discuss natural agents as well as pharmaceutical that are available for repair. Medications discussed include: Linzess, Amitizia, Trulance, Resolor


Ilana Gurevich, ND, LAc

$49 CAD

(1.0 hour)


Assessing the Microbiome in Gastrointestinal Health

Naturopathic doctors have always stressed the importance of treating the gut, and have used personalized diet to optimize health, botanical and other antimicrobials to treat stealth pathogens, and numerous other interventions to minimize harmful levels of inflammation and otherwise encourage best outcomes. How does the normal microbiome influence the importance and success of these treatments? How can emerging technology help us assess the importance of commensals and “possible pathogens?”


Mark Davis, ND

$49 CAD

(1.0 hour)


Updates in CRC Screening Guidelines

Colon cancer is the 3rd most common type of cancer in both men and women in the US. Naturopathic Physicians in a general medicine practice will inevitably see patients who have been diagnosed with colon cancer, or have a strong family history and thus risk factors for developing cancer. What is the role of the ND for these patients? Dr. Edwards provides an update on the most recent screening guidelines from the American Cancer Society which were changed in May 2018. Also a review of the more recent published research on integrative oncology for colon cancer is covered.


Eliot Edwards, ND, FABNO

$29 CAD

(0.5 hour)


Cannabinoids as Mediators of GI Function

The role of the endocannabinoid system in both physiological and pathophysiological function of the gastrointestinal tract is relatively unknown. Pharmacokinetic studies shed light on the metabolism and bioavailability of exogenous cannabinoids. Preclinical and clinical trials continue to explore the utility of using cannabinoids as therapeutic agents for gastrointestinal disorders. This presentation elucidates the key functions of the endocannabinoid system in maintaining gut function. It also summarizes existing evidence for using cannabinoids to treat GI disorders. Pharmaceuticals covered: Cannabidiol, Nabiximols, Dronabinol, Nabilone


Jamie Corroon, ND, MPH

$49 CAD

(1.0 hour)


Treat the Gut: Approaching Pediatric Constipation

Functional constipation is the most common reason for a GI referral in the pediatric population. Naturopathic medicine offers an extremely effective approach for treating these children that goes far beyond the routine laxative prescription. This presentation covers how to properly diagnose and treat constipation in this population and how to fill your toolkit with clinically applicable, evidence-based modalities that you can can immediately put into practice. This presentation also covers both pharmaceutical and non-pharmaceutical approaches to management. Polyethylene glycol, magnesium oxide and sennosides are reviewed.


Caitlin O’Connor, ND

$69 CAD

(1.5 hours)


Visceral Hypersensitivity: Causes, Consequences, and Therapeutic Approaches

Visceral hypersensitivity occurs in up to a third of patients with IBS and Functional Dyspepsia, two of the most common functional gastrointestinal disorders presenting to naturopathic practices. This condition is often overlooked and rarely discussed in clinical context, yet can complicate presentation and often leaves patients with continued symptoms despite “normal” work-up. This presentation reviews the proposed causes of visceral hypersensitivity, its relationship to IBS and FGID, and various treatment approaches, including review of research on pharmaceutical, botanical, manual, and psychological interventions. Review of pharmaceuticals to include classes of SSRI, TCA, 5HT3 antagonists, 5HT4 agonists, GABAnergic agents, as well as Ketotifen & Naltrexone (low dose).


Megan Taylor, ND

$69 CAD

(1.5 hours)

SIBO Symposium 2018

Title & DescriptionPresenter

Cost

(CE Hours)

All Presentations (including 3 expert panel discussions)
Multiple presenters

$499 CAD

(12 hours)


Exploring the Intersection between Eating disorders and SIBO/IBS

Disordered eating behaviors can have a profound impact on digestive physiology, resulting in changes to motility, anatomy, digestive secretions, immunologic status, and microbial balance. These changes often lead individuals with eating disorders to develop any number of functional gastrointestinal disorders (FGID), with some studies estimating a 98% prevalence of FGID in patients with an eating disorder (Boyd, et al. 2005). And to make matter more complex, the symptoms of the eating disorder itself can often be indistinguishable from the symptoms of these gastrointestinal disorders, making it difficult for clinicians to identify appropriate treatment strategies. This overlap can present challenges in the setting of a functional GI practice, and poses some difficult questions. How do we appropriately screen for and recognize patients who have eating disorders? How do we ensure that our interventions do not cause harm to these patients? Do we consider dietary modification or other cornerstones of digestive health treatments in this patient population? This presentation will explore these questions, as well as provide useful tools for clinical evaluation, management, and appropriate referrals for patients with disordered eating behavior and diagnosable eating disorders.


Megan Taylor, ND & Sara Hopkins, ND, LAc

$69 CAD

(1.5 hours)


Evolving Story of Autoimmunity in the Development of SIBO

It is becoming increasingly clear that SIBO is in some cases due to previous exposure to gastroenteritis. Through a series of interesting studies, it is now understood that this singe food poisoning event can lead to long term changes in the microbiome. The most important of these is the development of antibodies to vinculin. In this presentation, we will update the audience on the latest developments on this topic and how the future is shaping up to treat SIBO and IBS as an autoimmune condition.


Mark Pimentel, MD, FRCP(C)

$49 CAD

(1.0 hour)


Ehlers-Danlos Syndrome, Joint Hypermobility, POTS

Ehlers-Danlos and generalized joint hypermobility syndromes are common genetic connective tissues disorders that can present in a heterogenous pattern. This talk will discuss the subtypes of EDS, common comorbidities, red flag symptoms that indicate possible CNS involvement and a treatment approach to improving outcomes. We will also over a common co-morbidity, postural orthostatic tachycardia syndrome that can impact gastrointestinal motility and predispose patients to developing small intestinal bacterial overgrowth. We will discuss lifestyle and pharmaceutical approaches to treatment for POTS. The following medications will be discussed: Florinef, midodrine, beta-blockers, IV saline, low dose naltrexone, mestinon, and Corlanor.


Alena Guggenheim, ND

$49 CAD

(1.0 hour)


Mast Cell Activation Syndrome

Small intestinal bacterial overgrowth (SIBO) is a syndrome in that it has multiple causes. Motility disorders are most often the underlying factors to predispose for the development of SIBO. Postural orthostatic tachycardia syndrome (POTS) leads to an imbalanced autonomic nervous system because excessive sympathetic activity overrides vagal tone. Peristalsis is reduced and SIBO may be promoted. Mast cell activation syndrome (MCAS) is a leading factor in 33% of POTS. It is also conceivable that MCAS could directly impact motility via one of 200 mediators that may reduce neuromuscular activity. It is important to recognize POTS which has a prevalence of 500,000-1,000,000 in the US. Understanding this disease and the more prevalent MCAS (1 – 17% of the population) is critical to help many patients who otherwise suffer for decades without a diagnosis and/or effective therapy. 
Specific pharmaceutical medications to be discussed in both the overview and outline: rifaximin and naltrexone.


Leonard B. Weinstock, MD

$49 CAD

(1.0 hour)


The Importance of Gas Type in SIBO

In the last decade, the understanding of clinical breath testing in the evaluation of SIBO has evolved. We have come to know that methane on breath testing is highly associated with constipation and requires a different approach to treatment. Hydrogen on the other hand is not related to any specific symptom. The missing gas has been hydrogen sulfide and this gas is of great importance to the symptom diarrhea. Not having this gas in the breath test profile leaves a missing piece of the puzzle out. In this presentation we will examine the interaction of all three gases and the importance they play in the evolving microbiome story of SIBO. Rifaximin will be discussed which is FDA approved, neomycin a drug not yet approved for SIBO and SYN-010 which is not yet approved by FDA for methane.


Mark Pimentel, M.D., FRCP(C)

$29 CAD

(0.5 hour)



SIBO and the Thyroid: A Significant Relationship

In continuing the discussion of the principle of treating underlying causes of SIBO rather than simply focusing therapy on reduction of bacterial overgrowth, we cannot overlook the thyroid gland’s role in motility. Evidence has emerged for thyroid disorders as one of SIBO’s etiologies. This presentation explores SIBO’s intersections with dysthyroidsm, and points to implications in developing effective treatment plans and strategies for prevention of recurrence. The presentation will include a brief overview of thyroid prescribing, both clinically and sub-clinically, including use of Levothyroxin, Tri-iodothyronine, dessicated Thyroid USP, and compound prescribing.


Gary Weiner, N.D., L.Ac.

$49 CAD

(1.0 hour)


Pelvic Inflammatory Processes Part I: Endometriosis, Adenomyosis and Dysmenorrhea


The conditions of endometriosis, adenomyosis, and dysmenorrhea and their treatments have many consequences on the body. We will discuss how traditional management not only affects the pelvic inflammatory processes themselves but how it also impacts other inflammatory processes in the body, including SIBO. We will also show how pelvic inflammatory processes can have similar symptoms to SIBO. Pharmaceuticals to be discussed include: OCPs, Lupron, NSAIDS (including ponstel), Mirena IUD, Progestins (including norethindrone and Depo Provera), and Narcotics (including oxycodone and hydrocodone)

Pelvic Inflammatory Processes Part 2: PID, TOA and Ectopic Pregnancy – An Integrative Exploration


Pelvic inflammatory disease (PID), Tubo-Ovarian Abcesses (TOA) and ectopic pregnancy can have numerous negative effects on the body. We will discuss how traditional management not only affects these pelvic inflammatory processes but also how it impacts other inflammatory processes, including SIBO. We will expound on current theories regarding the possible etiologies of numerous pelvic inflammatory processes and how this impacts our understanding of other inflammatory processes, including SIBO. Pharmaceuticals to be discussed include: antibiotics such as azithromycin, Doxycycline, Ceftriaxone, Gentamicin and Flagyl as well as methotrexate


Lara Williams, MD, FACOG and Stefani Hayes ND, LAc

$89 CAD

(2.0 hours total)


The Parasite/SIBO Connection

This is a discussion of the connection between how both SIBO and parasitic infections affect the Microbiome and how one is often misdiagnosed as another. This will be a deeper look on how we currently understand how parasitic infections change the microbiome presentation and how patients will often suffer from and be diagnosed with one but the underlying cause is the other one. Alinia is briefly discussed as a use for treatment of parasitic infections.


Ilana Gurevich ND, LAc

$49 CAD

(1.0 hour)


Diabetic Enteropathy and SIBO

This presentation will explain how metabolic syndrome, prediabetes and frank diabetes become key underlying causes for SIBO and other GI disorders. The influences of lipopolysaccharides from overgrown flora, autonomic neuropathy, hepatic insulin resistance, effects of hyperglycemia and the hypothalamic-pituitary-adrenal axis on upper GI transit. SS-L will use example cases to show his approach to diabetes treatment and management. Pharmaceuticals to be discussed include: Metformin, berberine, allicin, oregano, ginger and neem will be discussed with regards to diabetes, insulin resistance and SIBO.


Steven Sandberg-Lewis ND, DHANP

$49 CAD

(1.0 hour)